Answers are grounded in this paper and cite their sources.
To the Editor: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that can be associated with inflammatory bowel disease (IBD).1 Treatment involves immunosuppression, starting with topical corticosteroids and increasing to more potent agents, including infliximab.1 Some cases are refractory and can be debilitating. We report the successful treatment of infliximab-refractory PG by adding tofacitinib as a second, concomitant agent. Our patient was diagnosed with ulcerative pancolitis at age 15 that failed multiple treatments, including adalimumab. She underwent a total abdominal colectomy with end ileostomy and Hartman pouch. She developed progressive deep ulcerations with defined borders and pathergy in her legs and around the stoma and was diagnosed with PG by dermatology. After inadequate response to intralesional steroids and dapsone, she was started on 5 mg/kg infliximab with some initial improvement. An increase in the dose of infliximab to 10 mg/kg every 4 weeks over 1 year (trough infliximab level, 22 mcg/mL) yielded no additional improvement in her PG lesions. Azathioprine at a dose of 200 mg by mouth daily and methotrexate 25 mg subcutaneous weekly were each tried as concomitant therapies with infliximab, without additional improvement. On recent examination, she had a persistent 1-cm ulcer with purple edges with surrounding erythema (Fig. 1A) next to the stoma, and there were 2 additional ulcers in the suprapubic and perianal region and another on the foot. Tofacitinib 10 mg twice daily was then added to infliximab. Three weeks after the addition of tofacitinib, the abdominal lesions had almost completely resolved (Fig. 1B) whereas the suprapubic and perianal ulcers had significantly improved. A, Peristomal PG with ulcer adjacent to stoma (arrow) before treatment with tofacitinib. B, Peristomal area with healed ulcer (arrow) 3 weeks after starting tofacitinib. Tofacitinib is a JAK inhibitor recently approved for ulcerative colitis. Kochar reported 3 cases of patients with IBD and PG prescribed tofacitinib for IBD-related arthritis, including 1 on concomitant vedolizumab, who had marked improvement in their skin lesions.2 Similar to our patient, their IBD seemed to be well controlled. The pathogenesis of PG is unclear, but JAK signaling has been implicated.2, 3 Mutations in JAK2 have been associated with PG,3 and Kochar found activation of the JAK-STAT pathway on skin biopsies for 2 patients.2 Given the dramatic and rapid response to concomitant tofacitinib and infliximab in our patient, future studies are needed to confirm the efficacy of tofacitinib in PG. Studies might include its concomitant use with other immune suppressants. Further studies should also consider the safety of this approach and the ability to withdrawal tofacitinib if used as a concomitant immunosuppressant. Conflict of interest: M.C.: speakers bureau or consulting for UCB, AbbVie, Pfizer, and Takeda; grant support from Incyte, AbbVie, and Takeda. P.D.: received consulting fees from Janssen and Pfizer, speaker fees from Abbvie, and a research grant from Takeda. M.H.G., G.C.: Each of these authors reports no disclosures or conflicts of interest relevant to this study. Supported by: No external funding was used for this project.
No takes yet. Share an insight, caveat, or question.
Gregory et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: